Sign In
Buy NXTC
$3.15
-0.250 (-7.35%)
At Close: Jun 03, 2026
Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?
10:55am, Tuesday, 11'th Nov 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in NextCure (NXTC). While the effectiveness of this highly sought-after metric is questionable, the posi
NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
04:05pm, Wednesday, 05'th Nov 2025
BELTSVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-i
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
08:05am, Thursday, 16'th Oct 2025
BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, and S
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
07:00am, Thursday, 04'th Sep 2025
BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-
NextCure (NXTC) Q2 Loss Widens 71%
11:32pm, Thursday, 07'th Aug 2025
NextCure (NXTC) Q2 Loss Widens 71%
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
04:05pm, Thursday, 07'th Aug 2025
BELTSVILLE, Md., Aug. 07, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-
BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-
NextCure signs up to $745 million deal with China's Simcere to develop cancer drug
10:03am, Monday, 16'th Jun 2025
Drug developer NextCure said on Monday it had signed a deal worth up to $745 million with China-based drugmaker Simcere Zaiming to develop a cancer therapy for solid tumors.
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
07:05am, Monday, 16'th Jun 2025
BELTSVILLE, Md. and SHANGHAI, June 16, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class
BELTSVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-c
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
04:05pm, Thursday, 01'st May 2025
Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025 Plan to provide a proof of concept data readout in the f
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
07:00am, Friday, 04'th Apr 2025
BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-
NextCure Provides Business Update and Reports Full Year 2024 Financial Results
04:05pm, Thursday, 06'th Mar 2025
BELTSVILLE, Md., March 06, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
08:05am, Friday, 10'th Jan 2025
BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-
NextCure Announces Acceptance of IND Application for LNCB74
08:05am, Tuesday, 10'th Dec 2024
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed fo
